Kolexia
Ferrant Emmanuelle Hématologie
Ferrant Emmanuelle
Hématologie
Hôpital Lyon Sud
Pierre-Bénite, France
98 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Leucémie chronique lymphocytaire à cellules B Lymphomes Leucémie lymphoïde Lymphome B Lymphome B diffus à grandes cellules Mucormycose Hémopathies Aspergillose

Collaborateurs

Voir plus
Sesques Pierre
Sesques Pierre
Hôpital Lyon Sud, Pierre-Bénite, France
Michallet Anne-Sophie
Michallet Anne-Sophie
Centre Léon-Bérard, Lyon, France
Ysebaert Loic
Ysebaert Loic
Oncopole Toulouse, Toulouse, France
Safar Violaine
Safar Violaine
Hôpital Lyon Sud, Pierre-Bénite, France

Industries

Voir plus
Janssen
39 collaboration(s)
Dernière en 2023
Gilead
17 collaboration(s)
Dernière en 2023
Abbvie
16 collaboration(s)
Dernière en 2023
AstraZeneca
14 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
BRUIN-CLL-314: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314)
Essai Clinique (Loxo Oncology, Inc.)   24 janvier 2024
BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
Essai Clinique (Loxo Oncology, Inc.)   24 janvier 2024
RESIST: REfractorinesS to Ibrutinib BTKi and Systemic Targeted Therapy
Essai Clinique (BMS)   06 décembre 2023
Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group
65th ASH Annual Meeting Abstracts   02 novembre 2023
Outcomes of CLL Patients Exposed to Venetoclax+/-R after Ibrutinib in France: The Resist Retrospective Study from the Filo-CLL Group
65th ASH Annual Meeting Abstracts   02 novembre 2023
Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-up of Elevate-TN
65th ASH Annual Meeting Abstracts   02 novembre 2023
Skeletal Muscle Index, As a Measure of Muscle Mass, Is a Significant Prognostic Factor for Newly Diagnosed Diffuse Large B-Cell Primary CNS Lymphoma Patients
65th ASH Annual Meeting Abstracts   02 novembre 2023
EVEREST: Assessment of the Quality of Life of Patients With Lymphomas Treated With Oral Therapy
Essai Clinique (CHU Toulouse)   18 septembre 2023
THEMIS: Targeted Therapies in Chronic Lymphocytic Leukemia and Medico-economic Evaluation of the Ambulatory Medical Assistance Nurse Program : a Prospective Multicenter Randomized Study
Essai Clinique (CHU Toulouse)   18 septembre 2023
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial.
Blood advances   28 juillet 2023